This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the preliminary efficacy.
Subjects with ability to understand and voluntarily agree to participate by giving written informed consent for the study.
Patients with unresectable recurrent or metastatic solid tumors.
There is at least one lesion that could be measured.
An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.
Patients with known active central nervous system (CNS) metastases.
Subjects who had other malignancy in five years before the first dose.
Patients with tumor-related pain that can not be controlled as determined.
Patients with serious cardiovascular and cerebrovascular diseases.
Single group
FH-006 for Injection
DrugFH-006 for injection.
Objective Response Rate (ORR)
ORR is the efficacy endpoint of FH-006 for injection monotherapy in treatment of patients with advanced solid tumors.
Time to maximum concentration (Tmax)
Maximum concentration (Cmax)
Terminal half-life (t1/2)
Area Under the Concentration Versus Time Curve From Time Zero to T (AUC0-t)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
